1.Incision of the intrarenal sinus supplemented by a postrenal pole segmental incision removal of huge calculus
Jie ZHANG ; Wujun CAO ; Yi YIN
Journal of Clinical Surgery 2001;0(04):-
Objective To evaluate the surgical treatment of huge staghorn stones. Method The clinic dates of 184 cases treated with an incision of the infrarenal sinus supplemented by a postrenal low pole segmental incision were studied. Result 184 cases were all successful.Conclusion We conclude that this method, need no interruption of renal blood flow had advantages of simple procedure less bleeding, completely removing calculi, protecting renal function.
2.Conversion from mycophenolic acid to mizoribine in renal transplant recipients with gastrointestinal tract symptoms: a prospective observational multi-center study
Bingyi SHI ; Jianxin QIU ; Weiguo SUI ; Jun TIAN ; Youhua ZHU ; Chunbo MO ; Changxi WANG ; Yingzi MING ; Zhishui CHEN ; Yaowen FU ; Zheng CHEN ; Longkai PENG ; Zhilin HU ; Tao LIN ; Xuyong SUN ; Hang LIU ; Ruiming RONG ; Ye TIAN ; Wujun XUE ; Ming ZHAO ; Guiwen FENG ; Ronghua CAO ; Decheng DENG ; Minzhuan LIN ; Xiaodong ZHANG
Chinese Journal of Organ Transplantation 2017;38(12):708-713
Objective To evaluate the effect of conversion from mycophenolic acid (MPA) to mizoribine (MZR) in renal transplant recipients with gastrointestinal tract (GI) symptoms.Methods A total of 355 renal transplant recipients with GI symptoms caused by MPA administration were enrolled from April 2015 to March 2017 in 25 different renal transplant centers in China.The symptomatic improvement of GI before (baseline) and after conversion to MZR (1,2,4 weeks) was assessed by each item of GI symptoms indication.In addition,the efficacy and safety of the conversion therapy during 12 months were determined.Results Patients showed improvement in GI symptoms including diarrhea,abdominal pain,abdominal distention and stomachache after conversion to MZR 1,2,4 weeks (P<0.05).In patients with different severity of diarrhea,conversion to MZR therapy significantly improved diarrhea (P<0.05).During 12 months,no patient experienced clinical immune rejection.We did not observe any infections,leucopenia and other serious side effects.Conclusion MZR could markedly improve GI symptoms caused by MPA administration in renal transplant recipients.